Where a Woman Lives May Affect Her Breast Cancer Treatment

Publication
Article
OncologyONCOLOGY Vol 22 No 6
Volume 22
Issue 6

Women in the Northeast US are more likely to receive breast-conservation therapy, while those in the South are more often recommended for mastectomies for the treatment of invasive breast cancer, according to a study presented at the 9th Annual Meeting of the American Society of Breast Surgeons (ASBS), held April 30 to May 4 in New York.


Women in the Northeast US are more likely to receive breast-conservation therapy, while those in the South are more often recommended for mastectomies for the treatment of invasive breast cancer, according to a study presented at the 9th Annual Meeting of the American Society of Breast Surgeons (ASBS), held April 30 to May 4 in New York. The study examined data in the massive American College of Surgeons National Cancer Database Benchmark Reports broken down by US census regions. It found that where a woman lives is a significant predictor of her initial invasive breast cancer treatment protocol, independent of such factors as race, age, economic status, and stage at diagnosis.

According to the research, 69.9% of women with breast cancer that has spread beyond the breast ducts or lobules into surrounding breast tissue have only a portion of the breast that contains the tumor removed (lumpectomy), while the remainder are treated with total breast removal (mastectomy). In the Western states, 62.8% receive conservation therapy, whereas conservation rates in the Midwest are 60.7% and in the South are 57.7%.

Recent Videos
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content